FFAR2 and graft versus host disease: To verify the influence of GPR43 dependent activation of the NLRP3 inflammasome for GVHD resistance, we administered propionate, which requires GPR43 to reduce GVHD (Fig. 3h, i), or butyrate, which only partially requires GPR43 for its anti-GVHD activity (Fig. 3f, g), to either [WT B6 → WT B6Ly5.2] or [WTB6 Ly5.2 → Nlrp3−/−] recipients following allo-BMT.